Livatag is a treatment presented in nanoparticles able to deliver doxorubicin in chemoresistant cells.
It was granted an orphan drug status in Europe and in the US.
The product is being evaluated in patients (via hepatic intra-arterial route) with advanced hepatocellular carcinoma.
BioAlliance Pharma CEO Dominique Costantini said Livatag is perfectly in line with their orphan product strategy and could be a significant value catalyst for the company.